Spectrum Pharmaceuticals has filed a patent for a method of promoting anti-tumor immune response in a subject by locally administering encapsulated interleukin 12 (IL-12). This method aims to enhance the body’s immune response against tumors. GlobalData’s report on Spectrum Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Spectrum Pharmaceuticals, Cancer treatment biomarkers was a key innovation area identified from patents. Spectrum Pharmaceuticals's grant share as of September 2023 was 56%. Grant share is based on the ratio of number of grants to total number of patents.
Method for promoting anti-tumor immune response using encapsulated il-12
A recently filed patent (Publication Number: US20230277628A1) describes a method for promoting an anti-tumor immune response in individuals in need. The method involves locally administering a pharmaceutical composition containing encapsulated interleukin 12 (IL-12) to the subject. IL-12 is a protein that plays a crucial role in stimulating the immune system's response against tumors.
The patent claims specify various aspects of the method. Firstly, the encapsulated IL-12 is administered intratumorally, directly into the tumor site. This targeted approach aims to enhance the immune response specifically within the tumor microenvironment. Additionally, the IL-12 is encapsulated in a semi-crystalline matrix, which may consist of semi-crystalline water-soluble polymers such as polyalkylene glycols, polyvinyl alcohols, and polysorbates, among others.
The pharmaceutical composition may also include excipients like poly(vinyl pyrrolidone), surfactants, sucrose, and glycine, as well as biocompatible polymers like polylactic acid and polyglycolic acid. Furthermore, the composition can contain additional agents and diluents or vehicles to optimize its effectiveness.
The encapsulated IL-12 can be derived from either mouse IL-12 or human IL-12, depending on the specific application. The dosage of the encapsulated IL-12 can range from 1 mg to 2000 mg, with a preferred range of 200 mg to 1600 mg in a single dosage.
The method described in the patent is applicable to various conditions that involve an anti-tumor immune response, including glioblastoma, Crohn's disease, ulcerative colitis, irritable bowel syndrome, gastrointestinal cancer, and celiac disease. Additionally, the patent suggests that the method can be combined with other agents or therapies, such as radiation therapy, to further enhance the anti-tumor immune response. The encapsulated IL-12 can be administered before, after, or concomitantly with the second agent or therapy, which may involve ionizing radiation as a targeted radiation therapy.
It is important to note that the patent specifies that the subject in need of the method can be a human. This suggests that the method is intended for use in human patients.
Overall, this patent describes a method for promoting an anti-tumor immune response by locally administering encapsulated IL-12 to individuals in need. The method's specific details, including the use of a semi-crystalline matrix and potential combination with other therapies, provide potential advancements in the field of cancer immunotherapy.
To know more about GlobalData’s detailed insights on Spectrum Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
